BioSpace News Archive

ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN) today announced it has received a favorable patentability opinion from the European Patent Office (EPO) acting as the International Examiner on a polymorph patent application for farudodstat which, if granted in the national stages, will extend effective patent protection for farudodstat until at least 2043.

JAMP Pharma Group, a leading company in the Canadian pharmaceutical industry for over 35 years, announces subject to Superior Court approval and the fulfillment of customary closing conditions, the acquisition of the assets of Pharmalab’s manufacturing facility in Lévis, which ceased operations in August 2023.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Neurogene Inc. today announced that Company management will participate in the following investor conferences.

Recce Pharmaceuticals Ltd announced the continuation of work within its Anti-Infective Research Unit at the Murdoch Children’s Research Institute, to streamline its ongoing preclinical programs while investigating new indications for future clinical trials.

NANO-X IMAGING LTD and Beilinson Hospital announced their collaboration to conduct a clinical study evaluating the Nanox.ARC 3D imaging system in a clinical outpatient setting at Beilinson Hospital.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company with marketed products and a pipeline of development candidates, announced that Seth Lederman, M.D., Chief Executive Officer, will present at The 6th International Congress on Controversies in Fibromyalgia in Brussels, Belgium on March 7, 2024.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 7, 2024, to report its fourth quarter and full year 2023 financial results and provide recent business progress.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced updates to its TSHA-102 program in clinical evaluation for the treatment of Rett syndrome.

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic and fibrotic pathways, announced that management will participate in two upcoming investor conferences.